JP Morgan Day 3: Intercept makes an appearance; Sarepta waits for FDA notes
This article was originally published in Scrip
Diversified big pharma and specialty pharmaceutical players have multiple pipeline programs to discuss with investors during the 32nd Annual JP Morgan Healthcare Conference, but news about a single drug candidate has the potential to make or break smaller companies.
You may also be interested in...
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.